SITE014-0391

completed

Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE014 (NLD) (Dr. Moreau) · consented 2023-06-24

Adverse events

Serious AEs

Open data queries

Luna dropout signal

–

Adverse events

severe assessed 2026-08-18

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-07-28 (study day 23); relationship: not assessed

severe serious assessed 2026-08-18

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-08-04 (study day 30); relationship: not assessed; serious criteria: hospitalization

moderate assessed 2026-08-18

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-09-05 (study day 62); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-10-11 (study day 98); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-12-09 (study day 157); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-12-16 (study day 164); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.